Docs Want Backup If Payers Balk At Denosumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's model with Gardasil could provide the fix for Amgen's osteo drug, too.
You may also be interested in...
Nearly A Quarter Of Diabetes Patients Altered Therapy In Part D Gap – Study
Twenty-three percent of a large sample of Medicare Part D enrollees taking oral drugs for diabetes changed their medication use when they reached the gap in coverage, according to a study released by the Kaiser Family Foundation Aug. 21
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.